(Q34376314)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

A A Kortt

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

O Dolezal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

P J Hudson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 October 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

95-108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

Creating and engineering human antibodies for immunotherapy

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Antibody engineering and its applications in tumor targeting and intracellular immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Monoclonal antibodies and therapy of human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Recombinant antibodies: a novel approach to cancer diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

1 reference

7 January 2021

Recombinant antibody constructs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

High avidity scFv multimers; diabodies and triabodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Generating improved single-chain Fv molecules for tumor targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Taking engineered anti-CEA antibodies to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Immunotoxins in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Bispecific antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

New protein engineering approaches to multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Single-chain antigen-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Retargeting serum immunoglobulin with bispecific diabodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Crystal structure of a diabody, a bivalent antibody fragment

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Triabodies: single chain Fv fragments without a linker form trivalent trimers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Three-dimensional structures of single-chain Fv-neuraminidase complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Single-chain Fv of anti-idiotype 11-1G10 antibody interacts with antibody NC41 single-chain Fv with a higher affinity than the affinity for the interaction of the parent Fab fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Phage diabody repertoires for selection of large numbers of bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

3 Protein engineering of single-chain Fv analogs and fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Anatomy of the antibody molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Intracellular and cell surface displayed single-chain diabodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Rapid production of single-chain Fv fragments in plants using a potato virus X episomal vector

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

High level production of soluble single chain antibodies in small-scale Escherichia coli cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

High-level temperature-induced synthesis of an antibody VH-domain in Escherichia coli using the PelB secretion signal

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment†

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Remodeling domain interfaces to enhance heterodimer formation

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Monoclonal antibodies for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Model and Simulation of Multivalent Binding to Fixed Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Tetravalent miniantibodies with high avidity assembling in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

A dimeric bispecific miniantibody combines two specificities with avidity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Complement recruitment using bispecific diabodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Enzyme immunoassays using bispecific diabodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Tumor-specific T-bodies: towards clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

Mutual Stabilization of VLand VHin Single-Chain Antibody Fragments, Investigated with Mutants Engineered for Stability†

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900090-9

7 January 2021

10.1016/S1389-0344(01)00090-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11566601%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference